If you have been reading about anti-doping category and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
== Derivatives == DS54360155, a novel compound with a unique and original bicyclic skeleton, is more a potent analgesic than conolidine in mice. DS39201083 and DS34942424 are other similar derivatives. They all lack mu-opioid activity. The researchers who found conolidine binding site ACKR3/CKCR7 also developed a synthetic analogue of it called RTI-5152-12. It displays an even greater activity on that receptor.
"prices for vaccines will be set as low as possible for territories that are or may be affected by an outbreak of a disease for which CEPI funding was used to develop a vaccine; "information, know-how and materials related to vaccine development must be shared with (or transferred to) CEPI" so that it can assume responsibility for vaccine development if a company discontinues expenditures for a promising vaccine candidate; CEPI would have access to, and possible management of, intellectual property rights (i.e., patents) for promising vaccines; "CEPI would receive a share of financial benefits that might accrue from CEPI-sponsored vaccine development, to re-invest in support of its mission to provide global public health benefit"; and data transparency among development partners should maintain the WHO Statement on Public Disclosure of Clinical Trial Results, and require results to be published in open-access publications. International groups, such as the Centre for Artistic Activism and Universities Allied for Essential Medicines, advocate for equitable access. Scientists have encouraged collaboration between the WHO, CEPI, corporations, and governments to ensure that vaccines are distributed in an evidence-based manner based on infection risk and to prioritize healthcare workers, vulnerable populations, and children. By mid-March 2021, 67 countries, mostly in Africa and the Middle East, had not yet reported any vaccinations. Countries that had begun vaccinations were generally prioritizing populations such as health workers or the elderly.
War within the Culture is mostly fought by the Culture's sentient warships, the most powerful of these being war-converted GSVs, which are described as powerful enough to oppose whole enemy fleets. The Culture has little use for conventional ground forces (as it rarely occupies enemy territory); combat drones equipped with knife missiles do appear in Descendant and "terror weapons" (basically intelligent, nano-form assassins) are mentioned in Look to Windward, while infantry combat suits of great power (also usable as capable combat drones when without living occupants) are used in Matter.
Sources: en.wikipedia.org
in military personnel exposed to high radiation, (during accidents at nuclear reactors), or to combat the action of toxic substances (including organophosphate compounds), combat traumas, as well as to prevent acute respiratory infections and flu. They were also used to treat laser retinal lesions in experimental animals exposed to a combat laser. All other peptide preparations, (natural and synthetic) are at different stages of studying in patients with different diseases. Among the important advantages of all designed peptide preparations is that they lack any toxic, allergic or adverse effects, this has been proven both in experimental and clinical studies. The main objective of studies for the recent decade was fundamental research devoted to the role that small peptides play in the evolution and development of living matter. It was crucial for understanding the mechanism of the action of peptides and evidencing their safety and effectiveness, whilst designing new medicinal preparations, dietary supplements, cosmetics and veterinary preparations.
The mechanism of the change in pore size is simple, the pores are smaller under LCST due to the elongated chains of PNIPAAm within the pores, as temperature increases to and above LCST, the chains retract into a globular formation increasing the pore size.
=== EURATOM === The European Atomic Energy Community (EURATOM) was founded on March 25, 1957, by the Treaty of Rome between France, Italy, the Benelux countries and the Federal Republic of Germany, and remains almost unchanged to this day. Chapter 3 of the Euratom Treaty regulates measures to protect the health of the population. Article 35 requires facilities for the continuous monitoring of soil, air and water for radioactivity. As a result, monitoring networks have been set up in all Member States and the data collected is sent to the EU's central database (EURDEP, European Radiological Data Exchange Platform). The platform is part of the EU's ECURIE system for the exchange of information in the event of radiological emergencies and became operational in 1995. Switzerland also participates in this information system.
=== Recent work === During the Edwards v. Aguillard case, Kenyon was co-authoring with Percival Davis, a creationist school textbook entitled Of Pandas and People, which was published in 1989. After the Edwards decision, all references to "creationism" were replaced with "intelligent design", with a reference to "creationists" being replaced by "design proponents". In the history of creationism, this is the origin of the term intelligent design and the link between creationism and intelligent design. In October 1992, Kenyon was told by the chair of the SFSU Biology Department to stop teaching creationism in introductory biology courses. He had been teaching creationism and intelligent design "for more than ten years," which received complaints from students and some faculty. Following the Chair's request, the faculty came out in support of Kenyon's academic freedom and ability to teach what he wanted without administration controlling topics. After a hearing, Kenyon "won the right to teach his iconoclastic view of the evolution of life." Kenyon claimed objections to his teaching rested on a positivist view of what constitutes legitimate science. Following the controversy, Kenyon entered talks with what became the Discovery Institute, including Stephen C. Meyer, Phillip E. Johnson, William Dembski and Michael Behe. He then became a Fellow of the Discovery Institute, which he remains today. The Institute is the driving force behind the intelligent design movement.
Sources: en.wikipedia.org
=== Social anxiety disorder === SSRIs show some evidence of effectiveness for social anxiety disorder, including reducing relapse and disability, but the overall quality of evidence is low to moderate and tolerability is slightly lower than placebo.
== Side effects == The US prescribing information for datopotamab deruxtecan includes warnings and precautions for interstitial lung disease/pneumonitis, ocular adverse reactions, stomatitis/oral mucositis, and embryo-fetal toxicity. Datopotamab deruxtecan is associated with a range of adverse events. The most common side effects are stomatitis, nausea, fatigue, alopecia (hair loss), constipation, vomiting, dry eye, keratitis, anemia, decreased appetite, increased aspartate transferase (AST), rash, diarrhea, neutropenia, and increased alanine aminotransferase (ALT).
== Development from 'Peptide 3' == 'Peptide 3' is a 12-amino acid linear peptide corresponding to amino acids 51 to 62 of mature human chemokine CCL2. It is formed from L-amino acids with the sequence NH2-Glu-Ile-Cys-Ala-Asp-Pro-Lys-Gln-Lys-Trp-Val-Gln-OH (or in single letter code NH2-EICADPKQKWVQ-OH). 'Peptide 3' was found to be a Broad-Spectrum Chemokine Inhibitor inhibiting chemotaxis of human myelomonocytic cell line THP-1 monocytes and human neutrophils induced by a range of chemokines including CCL2, CCL3, CXCL8 and CXCL12 with roughly equal potency of 10μM, but not migration induced by other non-chemokine chemoattractants such as n-formyl-Met-Leu-Phe (fMLP) or TGF-β. Biotinylated 'Peptide 3' was found to bind to THP-1 cells with a disassociation constant of roughly 10μM. This suggested that 'Peptide 3' functions as a chemokine receptor antagonist. This mechanism was later proved to not be in action.
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
Bacteriostatic water or sterile saline is commonly used to dissolve the powder. The choice of solvent affects stability and preservation. Aqueous solutions are kept refrigerated and are not intended for long-term storage.